The report "Lipid Nanoparticles Market by Product (Ionizable lipids, Phospholipids, Kits, Reagents), LNP Type (SLNs, NLCs), Molecule (siRNA, mRNA), Application, Service Type (Formulation Development, Manufacturing) - Global Forecast to 2029", is projected to reach USD 350.5 million by 2029 from USD 271.8 million in 2024, at a CAGR of 5.2% during the forecast period of 2024 to 2029. The lipid nanoparticles Services Market is projected to reach USD 238.1 million by 2029 from USD 135.5 million in 2024, at a CAGR of 11.9% during the forecast period of 2024 to 2029. Some factors contributing to the growth of the global market include increasing use of lipid nanoparticles in ant-cancer therapies, increasing use of lipid-nanoparticles in RNA-based therapies. Despite this, unfavorable regulatory scenario for lipid nanoparticles are expected to hinder market growth.
Browse 398 market data Tables and 53 Figures spread through 316 Pages and in-depth TOC on "Lipid Nanoparticles Market by Product (Ionizable lipids, Phospholipids, Kits, Reagents), LNP Type (SLNs, NLCs), Molecule (siRNA, mRNA), Application, Service Type (Formulation Development, Manufacturing) - Global Forecast to 2029"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/lipid-nanoparticles-market-70136984.html
In the lipid nanoparticles market, the segment of ionizable lipids held the biggest share in 2023.
Based on product, the lipid nanoparticles market is split into ionizable lipids, PEGylated lipids, neutral lipids, phospholipids, kits and reagents, additional formulation components, etc. Dominant on the market in 2023, ionizable lipids category is projected to dominate the market in the horizon of forecasts. High requirement for mRNA depending on which ionizable lipids segment causes great expansion. Segment of ionizable lipids is probably going to expand at notable CAGR over the projection period of 2024–2029 resulting from m-RNA based vaccination development.
The clinical application segment is estimated to register the highest growth rate during the forecast period in the lipid nanoparticles market.
Based on application, the lipid nanoparticles market is further segmented into commercial and clinical applications. The segment of clinical applications is expected to expand at faster rate during the horizon of forecasts. The main drivers of the expansion of the market are its ability to capture and apply a wide range of medicinal drugs; lipid nanoparticles (NPs) have become a flexible and very useful instrument in clinical research. The very important role lipid nanoparticles perform in the Their application in various fields of research is motivated by the evolution of precision medicine. Their ability to provide therapeutic drugs in an exact and effective way has transformed the way many different diseases were treated as well as the development of customised meds. Still, the strict rules should impede the expansion of the sector.
The Asia Pacific region will be the fastest-growing region of the lipid nanoparticles market in 2023.
Based on the region, the lipid nanoparticles market is segmented into six major regions: North America, Europe, Asia Pacific, Latin America, Middle East and Africa. The Asia Pacific is anticipated to register fastest growth in the lipid nanoparticles market owing to the rising incidence of chronic diseases, the rapid expansion of drug discovery & development projects, increasing R&D spending on biopharmaceutical projects, and the growth of the biotechnology industry in developing countries.
Key players in the lipid nanoparticles market include Avanti Polar Lipids (Croda International plc (US), Merck KGaA (Germany), Evonik Industries AG (Germany), FUJIFILM Pharmaceuticals U.S.A., Inc. (US), Nippon Fine Chemical (Japan), Recipharm AB (Sweden), Emergent (US), EUROAPI (France), Cayman Chemical (US), CordenPharma (Switzerland), NOF CORPORATION (Japan), Precision NanoSystems (Canada), Gattefossé (France), Acuitas Therapeutics (Canada), Creative Biolabs (US), Curapath (Spain), Lipoid GmbH (Germany), Nanocs, Inc. (US), MedKoo Biosciences, Inc. (US), Polysciences, Inc. (US), BIOVECTRA (Canada), Ascendia Pharmaceuticals (US), Curia Global, Inc. (US), IOI Oleo GmbH (Germany), and Vernal Biosciences (US).
Comments
0 comment